Nick Shaxson ■ Pfizer: tax dodger, price gouger
A new report from Americans for Tax Fairness concludes:
“In addition to dodging its fair share of taxes, Pfizer—maker of Celebrex, Lipitor, Lyrica, and Viagra, among many other health-care products—has also been aggressively raising prescription drug prices, thereby straining patients and our health care system and in some cases putting needed medications out of reach.
By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once. In the company’s biggest insult to America yet, Pfizer’s merger will allow it to go on enjoying all the benefits of being based here—everything from a publicly educated workforce to an excellent communications infrastructure to a reliable patent system—without adequately paying to support them.”
The two wealth-extracting techniques go together, very often. This is what modern capitalism is increasingly becoming.
Why doesn’t Pfizer’s leadership focus on what it was originally set up to do: wealth creation? And don’t get us started on shareholder value.
Related articles
🔴Live: UN tax negotiations – First Session
What to know and expect ahead of this week’s UN tax negotiations
The secrecy enablers strike back: weaponising privacy against transparency
Privacy-Washing & Beneficial Ownership Transparency
26 March 2024
Ireland (again) in crosshairs of UN rights body
Tax policy and gender disparity: A call to action on International Women’s Day 2024
Policy research conference: How a UN Tax Convention can address inequality in Europe and beyond
The IMF’s anti-money laundering strategy review is promising, but it all comes down to implementation
Inequality Inc.: How the war on tax fuels inequality and what we can do about it
Proposal for ‘Business in Europe: Framework for Income Taxation’ (BEFIT): A wrong turn in the right direction
2 February 2024